Overview
COAG market data
Price History
COAG price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.45 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $23.00 – $55.18 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.5B.
Company News
Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64Benzinga · Aug 12, 2026, 4:06 PM
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60Benzinga · Aug 11, 2026, 4:14 PM
8-K filing — Hemab Therapeutics Holdings, Inc. (COAG)SEC EDGAR · Aug 11, 2026, 11:11 AM
Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) EstimateBenzinga · Aug 11, 2026, 11:07 AM
Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 CongressBenzinga · Jul 14, 2026, 11:49 AM
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47Benzinga · Jul 13, 2026, 6:39 PM
Hemab Advances Bleeding Disorder PipelineBenzinga · Jul 13, 2026, 5:47 PM
CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55Benzinga · Jul 13, 2026, 1:32 PM
Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price TargetBenzinga · Jul 13, 2026, 1:14 PM
HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52Benzinga · Jul 13, 2026, 10:05 AM